Catalyst Reaction · NASDAQ: SLS · Biotechnology
SELLAS (SLS): Phase 3 data, a 156% session and a $13.00 offering
SELLAS Life Sciences (SLS) released positive pivotal Phase 3 REGAL trial data at 7:00 AM ET on Tuesday, November 17, and the stock went from Monday’s $7.47 close to as high as $34.00 before the open. It finished the session +156.4% at $19.15 on 15.7 times its 20-day average volume. After the close it proposed a $150 million offering, and on Wednesday night priced it at $13.00 a share. Here is how it traded, turn by turn, and how LiveChart’s stack read each one.
By IndicatorStack · · All times ET
The catalyst
What the company released or filed, to the minute it crossed. It’s in the timeline as a shaded row, linked to the source.
How it traded
The price around it, session by session: the gap, the range, the close, with the chart LiveChart draws from those bars.
How the stack read it
LiveChart’s read at each turn: the 5-minute trend (the stack bias), the higher timeframes (Compass), the flow (Undertow) and traps (Tripwire).
How the stack read it, checkpoint by checkpoint
The stack bias is LiveChart’s read of the 5-minute trend at that moment: a green dot is bullish, red bearish, grey no clear direction. Under it, what Compass read on the higher timeframes the trend is measured against.
- BeforeBearishMon close · $7.47Tailwind down
- Into the openBullishTue 9:30 AM · $24.04Tailwind up
- 30 minutes inBullishTue 10:00 AM · $17.79Tailwind up
- At the closeBearishTue 4:00 PM · $19.18Higher timeframes still up
- Wednesday’s closeBearishWed 4:00 PM · $17.94Higher timeframes still up
The timeline
Everything that happened, in order, on one ET clock: the company’s releases and SEC filings next to the price and the stack’s own turns.
- ReleaseSECShaded rows are the catalyst: the company’s own releases and filings
- PriceThe session’s open, high, low and close
- StackLiveChart’s 5-minute bias changed
- TriggerA hypothetical entry at the default settings
- TripwireA break of a level that failed to hold
Tuesday, November 17
- TriggerTrigger marked a long at $8.00Hypothetical, default settings: reached $31.02 at 8:30 AM for +287.8% (target)
- ReleasePositive pivotal Phase 3 REGAL trial dataPress release, GlobeNewsWire
- SECCurrent report (Form 8-K) filedAccepted by the SEC at 7:14:19 AM ET
- PricePremarket high $34.00+355.2% from the prior close
- Stack5-minute stack bias turned bullishat $25.25
- PriceOpened at $24.11+222.8% from Monday’s $7.47 close
- PriceSession low $16.70
- TripwireTripwire flagged a trap at the highsa push through resistance that failed to hold, at $21.33
- Stack5-minute stack bias went neutralat $20.16, its inputs no longer agreeing
- TriggerTrigger marked a long at $20.25Hypothetical, default settings: closed at $18.77 at 1:15 PM for −7.3% (stop)
- Stack5-minute stack bias turned bearishat $19.40
- TripwireTripwire flagged a trap at the lowsa push through support that failed to hold, at $18.97
- TriggerTrigger marked a short at $18.99Hypothetical, default settings: reached $16.98 at 4:05 PM for +10.6% (target)
- PriceClosed at $19.15, +156.4% on the day120M shares, 15.7× its 20-day average
- ReleaseProposed $150.0 million underwritten public offeringPress release, GlobeNewsWire
- SECProspectus supplement (Form 424B5) filedAccepted by the SEC at 4:14:29 PM ET
Wednesday, November 18
- Stack5-minute stack bias turned bullishat $19.05
- PriceOpened at $19.51+1.9% from Tuesday’s $19.15 close
- PriceSession low $17.22
- Stack5-minute stack bias went neutralat $17.64, its inputs no longer agreeing
- Stack5-minute stack bias turned bullishat $19.80
- PriceSession high $21.40
- Stack5-minute stack bias went neutralat $19.37, its inputs no longer agreeing
- Stack5-minute stack bias turned bearishat $18.70
- PriceClosed at $17.95, −6.3% on the day35.8M shares, 2.7× its 20-day average
- ReleasePricing of $150.0 million underwritten public offeringPress release, GlobeNewsWire
ScheduledThe offering is expected to closeper the company’s pricing release
Monday, November 16
Before the catalyst
SELLAS Life Sciences closed Monday at $7.47. The 5-minute stack bias was bearish (weakening), since 11:30 AM: under VWAP 7.67 and momentum down. Compass read “Tailwind down” (15m ↘ 1h ↘ 2h ↘ 4h ↘ D ↓). Undertow: volume surge, sellers hitting the bid. Tripwire: Shorts: Clean, nothing major in the way. Its Next row read “Bounce, resistance to hold at 7.67 (VWAP)”.
Over the year before, it had traded between $1.39 and $15.88. The week before, on Thursday, November 12, the company had announced third quarter 2026 financial results at 4:05 PM ET. The daily chart below shows where it was trading, and the bar the catalyst printed.
Bearishweakening · 5m stack bias · $7.47
- Compass
- Tailwind down
- Undertow
- Volume surge
- Tripwire
- Shorts: Clean
- Next
- Bounce, resistance to hold at 7.67 (VWAP)
Tuesday, November 17
The Phase 3 data and a 156% session
The release crossed at 7:00 AM ET, with the company’s Form 8-K accepted by the SEC at 7:14 AM. Premarket trading carried it to $34.00 by 8:30 AM, +355% from the prior close, on 702K shares before the bell. It opened at $24.11, +222.8%, and the regular session ranged from $16.70 to $24.89 before closing at $19.15. It did this on a day SPY fell 1.0% and XBI, the biotechnology ETF, fell 0.4%.
Into the open the stack read it as bullish (weakening) with 5 of 5 higher timeframes up, and Undertow read “sellers pushing back”. Thirty minutes in, the picture had changed: price was below VWAP at $20.79 and the Next row read “Lost VWAP 20.79, buyers need a reclaim”. By the close the 5-minute bias was bearish from 1:10 PM, while Compass still read “Higher timeframes still up”: the day’s trend on the 5-minute chart had turned while the higher timeframes it is measured against had not.
Bullishweakening · 5m stack bias · $24.04
- Compass
- Tailwind up
- Undertow
- Sellers pushing back
- Tripwire
- Longs: Clean
- Next
- Pullback, support to hold at 23.12 (slow EMA)
Bullishweakening · 5m stack bias · $17.79
- Compass
- Tailwind up
- Undertow
- Volume surge
- Tripwire
- Longs: Clean
- Next
- Lost VWAP 20.79, buyers need a reclaim
Bearishfirm · 5m stack bias · $19.18
- Compass
- Higher timeframes still up
- Undertow
- Sellers in control
- Tripwire
- Shorts: Clean
- Next
- Bounce, resistance to hold at 19.27 (slow EMA)
Wednesday, November 18
Between the offering’s proposal and its pricing
It opened at $19.51 (+1.9%) and traded from $17.22 to $21.40, closing at $17.95, −6.3% on 35.8M shares, still 2.7 times its 20-day average. The 5-minute stack bias was bearish (firm), since 2:00 PM: under VWAP 19.22 and a falling SMA, momentum down and trend strength with the sellers. Compass read “Higher timeframes still up” (15m ↘ 1h ↗ 2h ↗ 4h ↗ D ↗). Undertow: volume surge, sellers hitting the bid. Tripwire: Shorts: Clean, nothing major in the way.
After hours it last traded at $17.98, with Undertow reading “selling drying up”. Then, at 9:59 PM ET, the company published pricing of $150.0 million underwritten public offering: 11,538,462 shares at $13.00, 27.6% under the $17.95 close.
Bearishfirm · 5m stack bias · $17.94
- Compass
- Higher timeframes still up
- Undertow
- Volume surge
- Tripwire
- Shorts: Clean
- Next
- Selling drying up at 18.07, squeeze risk rising
Bearishweakening · 5m stack bias · $17.98
- Compass
- Higher timeframes still up
- Undertow
- Selling drying up
- Tripwire
- Shorts: Avoid
- Next
- Bounce, resistance to hold at 19.20 (VWAP)
Shares, float and insiders
The supply picture
What the company has outstanding, what the offering adds, and what its insiders and its share history show, from its SEC filings.
- Shares outstanding
- 204Mas reported to the SEC
- Float
- 202M99% of shares outstanding
- Offering
- 11.5M shares at $13.00$150M gross, plus an option on 1.7M more
- After the offering
- 215M shares+5.7% (+6.5% with the option)
- Value at the offering price
- $2.8Ball shares after the offering, at $13.00
- Reverse splits on record
- 31-for-50 reverse split, November 8, 2019; 1-for-30 reverse split, January 2, 2018; 1-for-20 reverse split, November 14, 2016
- Last insider purchase
- November 19, 202563K shares at $1.59 by Kalin Katherine Bach (director)
- Last insider sale
- December 5, 20226K shares at $2.61
Releases and filings
Sources
The company’s own releases and its filings with the SEC, newest first, each with the time it crossed.
- ReleasePricing of $150.0 million underwritten public offeringWed Nov 18, 9:59 PM ET · GlobeNewsWire
- SECProspectus supplement (Form 424B5)Tue Nov 17, 4:14 PM ET · SEC EDGAR
- ReleaseProposed $150.0 million underwritten public offeringTue Nov 17, 4:01 PM ET · GlobeNewsWire
- SECCurrent report (Form 8-K)Tue Nov 17, 7:14 AM ET · SEC EDGAR
- ReleasePositive pivotal Phase 3 REGAL trial dataTue Nov 17, 7:00 AM ET · GlobeNewsWire
- SECCurrent report (Form 8-K)Thu Nov 12, 4:07 PM ET · SEC EDGAR
- SECQuarterly report (Form 10-Q)Thu Nov 12, 4:00 PM ET · SEC EDGAR
- SECOwnership stake over 5% (Schedule 13G)Tue Nov 10, 9:15 AM ET · SEC EDGAR
In short
Questions
Why did SLS stock go up on November 17?
SELLAS Life Sciences (SLS) released positive pivotal Phase 3 REGAL trial data at 7:00 AM ET on Tuesday, November 17, and the stock went from Monday’s $7.47 close to as high as $34.00 before the open. It finished the session +156.4% at $19.15 on 15.7 times its 20-day average volume. After the close it proposed a $150 million offering, and on Wednesday night priced it at $13.00 a share. The reaction describes the sequence and infers no cause.
What did SELLAS Life Sciences announce on November 17, 2026?
SELLAS Life Sciences (SLS) released positive pivotal Phase 3 REGAL trial data at 7:00 AM ET on Tuesday, November 17. The company’s release and its Form 8-K are linked in the sources on this page.
How did SLS stock trade on November 17?
SLS opened at $24.11, +222.8% from the prior close of $7.47, traded between $16.70 and $24.89 in the regular session and closed at $19.15, +156.4%, on 120M shares.
What were the terms of the SLS offering?
SELLAS Life Sciences priced 11,538,462 shares of common stock at $13.00 a share, for gross proceeds of about $150 million, with a 30-day underwriters’ option on up to 1,730,769 more shares. The pricing was announced at 9:59 PM ET on Wednesday, November 18, and the offering was expected to close on November 20.
What does LiveChart’s stack read on SLS now?
The read on this page is fixed at each moment it describes. LiveChart reads SLS on every bar as it trades: open it on LiveChart for the current stack bias, levels and every layer.
Every catalyst on SLS
SLS’s catalyst history
This is SLS’s first Catalyst Reaction. Each time it moves on a release or a filing again, the reads line up here side by side, so how it reacts to its own news builds into a history.
| Session | The catalyst | The day | Next session | Stack bias at the close |
|---|---|---|---|---|
| Nov 17, 2026This reaction | Positive pivotal Phase 3 REGAL trial dataTrial data · 7:00 AM ET | +156.4% | −6.3% | Bearish |
Also on Tuesday, November 17
More Catalyst Reactions from that session
- Nov 1710:00 AM ETMPU+65.6%Mega Matrix (MPU): Former Polygon Labs and Mega Matrix Exec Colin, a 65.6% session and what followedCompany news746.1× avg volume
- Nov 178:55 AM ETAYTU+46.2%Aytu BioPharma (AYTU): shareholder Alert: Ademi LLP, a 46.2% session and what followedCompany news44.7× avg volume
- Nov 177:32 AM ETFRTT+77.7%Fort Technology (FRTT): record Year-to-Date revenues of $12 million, a 77.7% session and what followedCompany news38.2× avg volume
- Nov 177:00 AM ETSMTK+66.0%SmartKem (SMTK): merger partner Ferrox advances Global, a 66.0% session and what followedCompany news103.3× avg volume
- Nov 176:00 AM ETGLSI+35.9%Greenwich LifeSciences (GLSI): Acceptance of abstracts at SABCS 2026, a 35.9% session and what followedCompany news8.6× avg volume
- Nov 174:48 PM ETCUE−79.9%Cue Biopharma (CUE): quarterly results, a 79.9% drop and what followedEarnings28.8× avg volume
Every Reaction From Nov 17More Trial Data ReactionsSLS Catalyst HistorySLS on LiveChartTechnical Setups RadarAll Catalyst ReactionsIntraday Movers
Further reading: Gaps: continuation and exhaustionLow-float riskWhat VWAP tells youTrading around halts
General market information from the company’s releases, its SEC filings, the session’s prices and LiveChart’s reads. Prices are indicative. It describes what happened and when, infers no cause, takes no view on what comes next and is not a recommendation to buy or sell any security. Trigger trades are hypothetical. Read the Risk Disclosure.